MJFF

Proteos has proudly partnered with The Michael J. Fox Foundation to provide high-quality protein reagents to support Parkinson’s disease research.  In the past 9 months (September 2016 to June 2017), we have delivered protein reagents to 22 U.S. and 19 international locations in support of this research effort.

The Michael J. Fox Foundation's Strategy to Generate, Characterize, and Distribute Preclinical Alpha-Synuclein Research Tools for Molecular Biology presented at Neuroscience 2016.

The Michael J. Fox Foundation will be presenting a poster at this year’s conference describing the research tools program:  The Michael J. Fox Foundation's Strategy to Generate, Characterize, and Distribute Preclinical Alpha-Synuclein Research Tools for Molecular Biology

The Michael J. Fox Foundation (MJFF) first goal is to propel breakthroughs that Parkinson's sufferers can immediately feel in their day to day lives. The foundation realizes the importance of protein reagents in many applications related to treating Parkinson's disease. MJFF has partnered with Proteos who provides them with the best quality reagents to support research of Parkinson's disease.

Now available from the MJFF Research Tools Program is a conformation-specific rabbit monoclonal antibody raised against filament alpha-synuclein, which recognizes both oligomeric and filamentous alpha-synuclein. This project was done in partnership with Proteos, Inc.; Abcam; and Aarhus University.

New Alpha-synuclein Proteins Available

MJFF announced the commercial launch of human alpha-synuclein proteins including monomeric and filament versions, as well as protocols and specially formulated monomeric alpha-synuclein to generate pre-formed fibrils. This project was in partnership with Proteos, Inc., and the proteins were validated by the Jensen and Luk laboratories at Aarhus University and the University of Pennsylvania, respectively.